专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09980903B2 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract 有权
公开(公告)号：US09980903B2
公开(公告)日：2018-05-29
申请号：US13153211
申请日：2011-06-03
申请人： Bret Berner , Jenny Louie-Helm , John W. Shell , Barbara Shell
发明人： Bret Berner , Jenny Louie-Helm , John W. Shell
IPC分类号： A61K9/20 , A61K31/197 , A61K9/00 , A61K31/00 , A61K31/65 , A61K31/195 , A61K31/496
CPC分类号： A61K9/0065 , A61K9/20 , A61K9/2031 , A61K31/00 , A61K31/195 , A61K31/197 , A61K31/496 , A61K31/65 , Y02A50/473 , Y02A50/475 , Y02A50/481
摘要： Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.

2. 发明授权

US07976870B2 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract 有权
标题翻译：在胃肠道下部限制药物释放的胃保持性口服剂型
公开(公告)号：US07976870B2
公开(公告)日：2011-07-12
申请号：US10769574
申请日：2004-01-29
申请人： Bret Berner , Jenny Louie-Helm , John W. Shell
发明人： Bret Berner , Jenny Louie-Helm , John W. Shell
IPC分类号： A61K9/22 , A61K9/20 , A61K9/32
CPC分类号： A61K9/0065 , A61K9/20 , A61K9/2031 , A61K31/00 , A61K31/195 , A61K31/197 , A61K31/496 , A61K31/65 , Y02A50/473 , Y02A50/475 , Y02A50/481
摘要： Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.
摘要翻译：提供了控制释放的口服剂型，用于将药理学活性剂连续，持续给药至患有进食模式的患者的上消化道。大多数药剂在延长释放的基础上被递送到小肠的胃，十二指肠和上部区域，药物在下胃肠道和结肠中的输送受到限制。所述剂型包含生物相容的亲水性可侵蚀聚合物与其中掺入活性剂的基质，其中所述聚合物是在水存在下溶胀并在数小时内逐渐侵蚀的聚合物，其起始于膨胀和侵蚀接触胃液，药物释放率主要受侵蚀速度控制。

3. 发明授权

US06488962B1 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms 有权
标题翻译：片剂形状以增强可膨胀控释口服剂型的胃滞留
公开(公告)号：US06488962B1
公开(公告)日：2002-12-03
申请号：US09598061
申请日：2000-06-20
申请人： Bret Berner , Jenny Louie-Helm
发明人： Bret Berner , Jenny Louie-Helm
IPC分类号： A61K914
CPC分类号： A61K9/0065 , A61K9/2031 , A61K9/2072
摘要： The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.
摘要翻译：口服药物剂型在胃中的保留通过使用可膨胀的剂型来改善，其可以以防止它们因特定方向而无意地穿过幽门的方式成型。形状的平面突起是具有不同长度的两个正交轴的平面突起，其长度足够短以允许在肿胀之前容易吞咽，而较短的时间足以在半小时内膨胀以防止通过幽门。

4. 发明授权

US08329215B2 Shell and core dosage form approaching zero-order drug release 有权
标题翻译：壳和核心剂型接近零级药物释放
公开(公告)号：US08329215B2
公开(公告)日：2012-12-11
申请号：US13156225
申请日：2011-06-08
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/52 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

5. 发明授权

US08043630B2 Shell-and-core dosage form approaching zero-order drug release 有权
标题翻译：壳和核心剂型接近零级药物释放
公开(公告)号：US08043630B2
公开(公告)日：2011-10-25
申请号：US12770283
申请日：2010-04-29
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/52 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

6. 发明申请

US20100272808A1 Shell-and-Core Dosage Form Approaching Zero-Order Drug Release 有权
标题翻译：壳和核心剂量形式接近零级药物释放
公开(公告)号：US20100272808A1
公开(公告)日：2010-10-28
申请号：US12770283
申请日：2010-04-29
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/10 , A61K31/155 , A61K31/337 , A61K31/401 , A61K31/7048 , A61K31/70 , A61K31/522 , A61K31/341 , A61K31/197 , A61K31/198 , A61K31/135 , A61K31/4365 , A61K38/14 , A61K31/43 , A61K31/545 , A61K31/496 , A61K38/13 , A61K31/7072 , A61P1/00
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

7. 发明授权

US07736667B2 Shell-and-core dosage form approaching zero-order drug release 有权
标题翻译：壳和核心剂型接近零级药物释放
公开(公告)号：US07736667B2
公开(公告)日：2010-06-15
申请号：US10213823
申请日：2002-08-07
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/52 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also promotes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to a size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。外壳还通过在胃液吸收到在餐后或喂食模式下保留在胃中的尺寸时膨胀而促进剂型的胃滞留。

8. 发明授权

US07405238B2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach 有权
标题翻译：用于增强药物给予胃的喂养模式的药理学诱导
公开(公告)号：US07405238B2
公开(公告)日：2008-07-29
申请号：US10235076
申请日：2002-09-04
申请人： Micheline Markey , John W. Shell , Bret Berner
发明人： Micheline Markey , John W. Shell , Bret Berner
IPC分类号： A61K31/21 , A61K47/00
CPC分类号： A61K9/0065 , A61K9/209 , A61K9/5084
摘要： Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of various substances that have been discovered to function as potent agents for inducing the fed mode. By inducing the onset of the fed mode, these agents cause the stomach to prolong its retention of the drug delivery system, which is either large enough to be retained in the stomach during the fed mode or swells or expands to such a size upon ingestion. The fed mode inducing agents include the following compounds and their salts: glycine and glycylglycine, xylitol and related sugar alcohols, sodium and other metal docusates, β-casomorphins, α-lipoic acid and similarly structured acids, 2,2-diaryl-4-(4′-aryl-4′-hydroxypipendino)butyramides, arginine, Trp-Trp, alkylpyridinium halides, dihydroxybenzoic acids, and potent sweeteners such as aspartame, aspartic acid, acesulfame, and stevioside.
摘要翻译：预期用于在胃或上肠道中吸收的药物在口服药物递送系统中与已被发现用作诱导喂养模式的有效药剂的任何各种物质一起施用。通过诱导进食模式的发作，这些药物引起胃部延长其药物递送系统的保留，药物递送系统的大小足以在进食模式期间保留在胃中，或者在摄食时膨胀或膨胀至这样的大小。饲喂模式诱导剂包括以下化合物及其盐：甘氨酸和甘氨酰甘氨酸，木糖醇和相关糖醇，钠和其他金属多库酯，β-半胱氨酸，α-硫辛酸和类似结构的酸，2,2-二芳基-4- （4'-芳基-4'-羟基磷脂）丁酰胺，精氨酸，Trp-Trp，烷基吡啶鎓卤化物，二羟基苯甲酸，以及强效甜味剂，如阿斯巴甜，天冬氨酸，乙酰磺胺酸和甜菊苷。

9. 发明授权

US09017667B2 Dosage forms that facilitate rapid activation of barley protease zymogen 有权
标题翻译：促进大麦蛋白酶酶原快速活化的剂型
公开(公告)号：US09017667B2
公开(公告)日：2015-04-28
申请号：US13123219
申请日：2009-10-09
申请人： Bret Berner
发明人： Bret Berner
IPC分类号： A61K38/48 , A61K9/20 , A61K9/48 , A61K9/50 , C12N9/50 , A61K9/16
CPC分类号： A61K38/4873 , A61K9/1623 , A61K9/2013 , A61K9/2077 , A61K9/2095 , A61K9/4858 , A61K9/5042 , A61K9/5084 , C12N9/50
摘要： The therapeutic efficacy of zymogen proteins for oral administration is improved by including in the formulation one or more excipients that optimize pH and other reaction conditions for rapid activation of the zymogen shortly after ingestion.
摘要翻译：通过在制剂中包含一种或多种优化pH和其他反应条件以在摄入后不久快速激活酶原的赋形剂来改善酶原蛋白质用于口服给药的治疗功效。

10. 发明授权

US09000046B2 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract 有权
标题翻译：胃酸滞留剂用于将阿坎酸延长释放到上消化道
公开(公告)号：US09000046B2
公开(公告)日：2015-04-07
申请号：US13247956
申请日：2011-09-28
申请人： Bret Berner , Cuiping Chen
发明人： Bret Berner , Cuiping Chen
IPC分类号： A61K31/16 , A61K9/22 , A61K9/26 , A61K31/185 , A61K9/00 , A61K9/20
CPC分类号： A61K9/0065 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K31/185 , A61K47/10
摘要： Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
摘要翻译：描述了用于持续释放阿坎酸的胃滞留剂型，其可以允许急性和长期治疗包括酒精依赖性，耳鸣，睡眠呼吸暂停，帕金森病，左旋多巴诱导的帕金森氏症运动障碍的疾病的每日一次或两次疾病，阿尔茨海默病，亨廷顿舞蹈病，肌萎缩性侧索硬化，皮质扩张抑郁症，偏头痛，精神分裂症，焦虑症，迟发性运动障碍，痉挛性，多发性硬化，各种类型的疼痛或暴饮暴食。还描述了使用剂型和制备剂型的方法的治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式